TO THE EDITOR
The translocation t(11;14) involving immunoglobulin heavychain gene switch region and cylin D1 is the most common IgH translocation (15-20%) in multiple myeloma (MM).
1,2 MM patients with t(11;14) are considered in some studies to have a better prognosis when treated with either conventional chemotherapy or autologous stem cell transplant. 3, 4 In contrast, patients with chromosome 13q deletions (40-50%) have a poor prognosis. [5] [6] [7] These results would predict that long-term survivors of MM would more frequently harbor a t(11;14) but not a 13q deletions. To address this, we used cytoplasmic Igenhanced fluorescence in situ hybridization (cIg-FISH) to evaluate clonal plasma cells for t (11;14) and 13q status from 20 long-term survivor MM cases.
All of these patients met the diagnostic criteria for MM before May 1995 and have survived greater than or equal to 8 years from diagnosis at the time of analysis. The 11 male and nine female had a median age of 52 years (range 39-62 years), with a median bone marrow plasmacytosis of 30% (range, 10-80%) at diagnosis. None of these cases had smoldering myeloma or MGUS using standard definitions. In all, 11 had IgG, six IgA, two free light chains and one nonsecretory. Of the 20 patients, 17 received autologous stem cell transplantation. The median duration between diagnosis to transplant was 24 months (range 5-149 months), and the median progression-free survival (PFS) after transplant was 32 months (range, 1-62 months). One patient died 3 years after transplant and 10 years after diagnosis. The other 19 patients remain alive.
We used cIg-FISH with a fusion strategy for detection of t(11;14). The IgH probe labeled with SpectrumGreen and the cyclin D1 probe labeled with SpectrumRed were obtained from Vysis (Downers, Grove, IL, USA). A patient was considered to have t(11;14) if the percent of clonal plasma cells exceeded 10% of signals with a abnormal pattern (fusions) indicative of a t(11;14). All of the cases were also tested for chromosome 13q status using the probes LSI CEP8 and D13S319 as described previously.
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Of the 20 cases, t(11;14) was detected in only one patient with 94% clonal plasma cells involved. This patient who had PFS of 20 months after autologous stem cell transplant and is alive B3 years post-transplant and 10.5 years after initial diagnosis. Chromosome 13q deletions were found in three cases (15%), with a median of 43% clonal plasma cells involved. All three patients are alive.
Since only one (5%) of the long-term MM survivors harbored t(11;14), this study argues against a major role of t(11;14) in prolonging the survival of these MM patients. Hence, despite its association with a better prognosis, our results suggest that t(11;14) should not be used as a predictor for long-term survivors in MM. As anticipated, 13q deletions were infrequent in this group of MM. Resistance to Fas-mediated apoptosis is a characteristic of Hodgkin and Reed-Sternberg (HRS) cells, the malignant cell population in cHL. 1 The CD95/Fas (further on referred to as Fas) protein is a transmembrane death receptor, activation of which by its ligand FasL leads to initiation of a signaling cascade that terminates in apoptotic cell death. Several observations link Fas resistance to malignant transformation of HRS cells: Germinalcenter (GC) B cells, the precursor cells of HRS cells, are being stringently selected for expression of a high-affinity and non-selfreactive B-cell receptor (BCR). This selection process specifically involves activation of the Fas-signaling pathway.
2 Since HRS cells show crippling mutations (eg premature stop codons) in rearranged immunoglobulin genes leading to ablation of BCR expression in 25% of cases, and given the lack of BCR expression in virtually all cases, the HRS cell precursor cells apparently arise in the GC without undergoing antigenic selection, but rather escape Fas-mediated apoptosis.
1 Furthermore, in patients suffering from the inherited autoimmune lymphoproliferative syndrome (ALPS) -caused by heterozygous germline mutations of the TNFRSF6 gene encoding Fas -the risk for development of Hodgkin's lymphoma (HL) is increased 50-fold.
3 In contrast, the risk for development of non-Hodgkin's lymphoma (NHL) of various subtypes is increased 14-fold, suggesting that inactivation of Fas is particularly permissive for the development of HL.
3 Additionally, somatic TNFRSF6 gene mutations have been found in approximately 20% of GC or post-GC-derived B-cell NHL corroborating the view that Fas can act as a tumor suppressor in GC-derived lymphomas.
2 However, sequence analysis of the TNFRSF6 gene in primary HRS cells revealed destructive mutations in only B10% of the cases. 4 Taken together, these observations suggest that the evolving HRS cell clone may be selected for inactivation of the Fassignaling pathway in which somatic mutations of the TNFRSF6 gene play only a minor role.
We hypothesized that mutations in other genes involved in apoptotic signaling from cell-surface death receptors might be involved in apoptosis resistance in cHL. The proteins caspase-8, caspase-10 and FADD are recruited to the intracellular part of Fas upon activation where they constitute the death-inducing signaling complex (DISC). DISC formation is a critical event in the initiation of Fas-mediated death signals. The genes CASP8, CASP10 and FADD encoding the proteins caspase-8, caspase-10 and FADD were therefore chosen for this analysis. Additionally, mutations in the CASP10 gene have been identified as the underlying cause of another subtype of ALPS lacking TNFRSF6 mutations, termed ALPS type II. Moreover, somatic mutations in the CASP10 gene were recently found in about 15% of NHL, most of them being GC B-cell derived. 5 Thus, all coding exons of the CASP8, CASP10 and FADD genes were amplified, and directly sequenced from DNA of cHL cell lines L1236, L428, KM-H2 and L591 (Table 1) . To address the question whether single alleles of CASP8, CASP10 or FADD genes might be inactivated in cHL cell lines by large chromosomal deletions, we analyzed the sequences for the presence of known monoallelic single nucleotide polymorphisms (SNPs) indicated by 'double peaks' in the electropherograms (ie presence of wild-type and polymorphic allele). The detection of such double peaks in at least one exon of the CASP8 and CASP10 genes in all four cell lines analyzed indicates amplification of both alleles, excluding the possibility that single alleles of these genes might be affected by chromosomal deletions in these cases. In the case of FADD, heterozygous SNPs were only detected in KM-H2 and L591 cells. We can therefore not formally rule out inactivation of single FADD alleles by large deletions in L1236 and L428 cells. Further analyses of the sequences revealed lack of somatic CASP8, CASP10 and FADD gene mutations in all cell lines analyzed. Taken together, the HRS cell lines L1236, L428, KM-H2 and L591 lack somatic mutations or large chromosomal deletions of
